Investigation Report on China’s Infliximab Market 2022-2031

$3,200$4,800

According to CRI’s market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China’s infliximab market.

Description

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen’s infliximab a challenge in the Chinese market.

According to CRI’s market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab’s sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI’s market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China’s infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict “COVID-19 dynamic zeroing” policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.

 

Topics Covered:

  • The impact of COVID-19 on China’s Infliximab market
  • Sales value of China’s Infliximab 2017-2021
  • Competitive landscape of China’s Infliximab market
  • Prices of Infliximab in China
  • Prices of Infliximab in China by regions and manufacturers
  • Analysis on factors affecting the development of China’s Infliximab market
  • Prospect of China’s Infliximab market from 2022 to 2026

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2022

Base Market Size

285.65

Currency

CNY million

Forecast Year

2031

Market Size Forecast

701.61

CAGR

10.50%

Table of Contents

1 Relevant Concepts of Infliximab

1.1 Indications for Infliximab

1.2 Development of Infliximab in China     

1.3 Governmental Approval of Infliximab in China

1.4 The Impact of COVID-19 on Infliximab sales in China

 

2 Sales of Infliximab in China, 2017-2021  

2.1 Sales Value of Infliximab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region 

2.2 Sales Volume of Infliximab    

2.2.1 Overall Sales Volume  

2.2.2 Sales Volume by Regions    

2.3 Sales of Infliximab by Dosage Form in China, 2017-2021   

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

      

3 Analysis of Major Infliximab Manufacturers in China, 2017-2021  

3.1 Analysis of Market Share of Major Infliximab Manufacturers     

3.1.1 Investigation on Market Share by Sales Value    

3.1.2 Investigation on Market Share by Sales volume 

3.2 Janssen Biologics BV     

3.2.1 Enterprise Profile 

3.2.2 Sales of REMICADE (Janssen’s Infliximab) in China

 

4 Prices of Infliximab for Different Manufacturers in China, 2021-2022

4.1 Janssen Biologics BV (REMICADE)    

 

5 Prospect of Chinese Infliximab drug Market, 2022-2031

5.1 Influential Factors of Chinese Infliximab Market Development

5.1.1 The Impact of COVID-19 on Chinese Infliximab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size 

5.3 Forecast on Market Trend

 

List of Charts

Chart Infliximab Drugs Approved by Chinese Government, by 2022 

Chart Sales Value of Infliximab in China, 2017-2021 

Chart Sales Value of Infliximab in Regions of China, 2017-2021 

Chart Sales Volume of Infliximab in China, 2017-2021

Chart Sales Volume of Infliximab in Regions of China,2017-2021    

Chart Sales value and volume of infliximab injection in China 2017-2021 

Chart Market Share of TOP3 Infliximab Manufacturers by Sales Value in China, 2017-2021

Chart Market Share of TOP3 Infliximab Manufacturers by Sales Volume in China, 2017-2021

Chart Profile of Janssen Biologics BV 

Chart Sales Value of Janssen Biologics BV ‘s Infliximab in China, 2017-2021  

Chart Sales Volume of Janssen Biologics BV ‘s Infliximab in China, 2017-2021

Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.

Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.’s Infliximab in China, 2017-2021

Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. ‘s Infliximab in China, 2017-2021

Chart Hisun Biopharmaceutical Co., Ltd.    

Chart Sales Value of Xi’an Hanfeng Pharmaceutical Co., Ltd.’s Infliximab in China, 2017-2021

Chart Sales Volume of Xi’an Hanfeng Pharmaceutical Co., Ltd.’s Infliximab in China, 2017-2021

Chart Prices of Janssen Biologics BV’s Infliximab (Remicade ®) in Parts of China, 2021-2022

Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.’s Infliximab (Leiting®) in Parts of China, 2021-2022    

Chart Prices of Hisun Biopharmaceutical Co., Ltd.’s infliximab(Anbaite®) in Parts of China, 2021-2022

Chart Forecast on sales of infliximab in China 2022-2031

Companies Mentioned

Janssen Biologics BV (REMICADE)

Reviews

There are no reviews yet.

Be the first to review “Investigation Report on China’s Infliximab Market 2022-2031”